المؤلفون: Daniel Seung Kim, Emily L. Chu, Emily E. Keamy-Minor, Ishan Dhananjay Paranjpe, Wilson L. Tang, Jack W. O’Sullivan, Yaanik B. Desai, Michael B. Liu, Elise Munsey, Kimberly Hecker, Isabella Cuenco, Beth Kao, Ellen Bacolor, Colleen Bonnett, Andrea Linder, Kathleen Lacar, Nancy Robles, Cindy Lamendola, Allysonne Smith, Joshua W. Knowles, Marco V. Perez, Masataka Kawana, Karim I. Sallam, Chad S. Weldy, Matthew T. Wheeler, Victoria N. Parikh, Heidi Salisbury, Euan A. Ashley, the Stanford Center for Inherited Cardiovascular Disease, Karim I Sallam, Chad S Weldy, Marco Perez, Joshua W Knowles, Jason Tso, Julia Platt, Chloe Reuter, Tia Moscarello, Ryan Murtha, Jennifer Kohler, Hannah Ison, Mitchel Pariani, Anusha Klinder, Priya Nair, Jennifer Marino, Ruchi Patel, Matthew T Wheeler, Euan A Ashley, Victoria N Parikh

المصدر: Frontiers in Cardiovascular Medicine, Vol 11 (2024)

مصطلحات موضوعية: mavacamten, MYK-461, hypertrophic cardiomyopathy, cardiac myosin inhibitor, hypertrophic cardiomyopathy with obstruction (oHCM), hypertrophic obstructive cardiomyopathy (HOCM), Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fcvm.2024.1429230/full; https://doaj.org/toc/2297-055X

URL الوصول: https://doaj.org/article/10cfc802d1ec46fb9a4e39b0fd818be9